Reports
Sale
Global Erythropoietin Drugs Market Size, Share, Growth, Trends, Forecast: By Drug Type: Biologics, Biosimilars; By Product Type: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others; By Application: Hematology, Kidney Disorder, Cancer, Others; By End User: Hospitals, Homecare, Others; Regional Analysis; Supplier Landscape; 2023-2031
Global Erythropoietin Drugs Market Outlook:
The global erythropoietin drugs market was valued at USD 10.3 billion in 2022, driven by the increasing prevalence of chronic kidney diseases and diabetes, cancer across the globe. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2023-2031 to achieve a value of USD 17 billion by 2031.
Erythropoietin Drugs: Introduction
Erythropoietin is a hormone solely produced by the kidneys in a human body. This hormone helps in generating enough erythrocytes (red blood cells) in body by delivering proper amount of oxygen among body tissues. When this oxygen turns into energy, carbon dioxide releases. Red blood cells are also responsible for delivering carbon dioxide to the lung to exhale it out of the body. Usually, when low oxygen levels are encountered, the specialized cells located in the kidneys boosts the production of Erythropoietin.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends in the Erythropoietin Drugs Market
These drugs are widely used for the treatment of anemia, kidney diseases, cancer, and patients undergoing chemotherapies or dialysis. These drugs can be consumed in the form of injections or subcutaneous implants. Stimulation of bone marrow helps erythropoietin drugs to produce more red blood cells, resulting in improved capacity of carrying oxygen, and relieve the symptoms related with anemia.
There are several key trends running in the market and some of them include the rising prevalence of chronic kidney diseases. The rise in ageing population is causing increased prevalence of diabetes and hypertension, leading to higher demand for erythropoietin drugs. Along with it, the increasing use of these drugs in oncology, advancements in drug delivery systems, expiration of biosimilars and patents are also among the key trends aiding the market growth.
Erythropoietin Drugs Market Segmentations
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Drug Type
- Biologics
- Biosimilars
Market Breakup by Product Type
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Market Breakup by Application
- Haematology
- Kidney Disorder
- Cancer
- Others
Erythropoietin Drugs Market Scenario
The global market size for erythropoietin drugs has been constantly growing and is expected to witness gradual growth in future as well. The increasing prevalence of anaemia and increasing demand for biosimilar and biological drugs are directly contributing to the growth of market size. The major cause of anaemia such as unhealthy diets and increasing chronic diseases, along with intestinal issues, and some other infections are increasing the demand for biosimilar drugs, and directly contributing to the growth of the erythropoietin drugs market size.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Due to the increasing rate of development of anaemia in more people the demand for erythropoietin drugs has also increased as they are approved by healthcare professionals easily and the research authorities. These fast approvals result in increased availability and increased production of the drug to directly support the growth of the erythropoietin drug market size.
Competitor landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche AG
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- LG Chem Ltd.
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd
- Amgen Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Product Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Erythropoietin Drugs Market Overview
3.1 Global Erythropoietin Drugs Market Historical Value (2016-2022)
3.2 Global Erythropoietin Drugs Market Forecast Value (2023-2031)
4 Global Erythropoietin Drugs Market Landscape
4.1 Image Guided Surgery: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Image Guided Surgery: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
5 Global Erythropoietin Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Erythropoietin Drugs Market Segmentation
6.1 Global Erythropoietin Drugs Market by Drug Type
6.1.1 Market Overview
6.1.2 Biologics
6.1.3 Biosimilars
6.2 Global Erythropoietin Drugs Market by Product Type
6.2.1 Market Overview
6.2.2 Epoetin-alfa
6.2.3 Epoetin-beta
6.2.4 Darbepoetin-alfa
6.2.5 Others
6.3 Global Erythropoietin Drugs Market by Application
6.3.1 Market Overview
6.3.2 Hematology
6.3.3 Kidney Disorder
6.3.4 Cancer
6.3.5 Others
6.4 Global Erythropoietin Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Clinics
6.4.5 Others
6.5 Global Erythropoietin Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Erythropoietin Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Erythropoietin Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Erythropoietin Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Erythropoietin Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Erythropoietin Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Amgen Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Biocon Limited
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Dr. Reddy’s Laboratories Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 F. Hoffmann-La Roche AG
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Intas Pharmaceuticals Ltd.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Johnson & Johnson
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 LG Chem Ltd.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Pfizer Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Sun Pharmaceutical Industries Limited
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Teva Pharmaceutical Industries Ltd.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global market was valued at USD 10.3 billion in 2022.
The global erythropoietin market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2023-2031 and reach a market value of USD 17 billion by 2031.
The rising incidence and prevalence of chronic kidney disease and cancer worldwide are the major drivers for the global erythropoietin market.
The different types of drugs in the market are biologics and biosimilars.
The different type of products in the market includes epoetin-alfa, epoetin-beta, and darbepoetin-alfa, among others.
The end users of the erythropoietin drugs include hospitals, homecare, and speciality clinics, among others.
The different applications of erythropoietin drugs include haematology, kidney disorder, cancer, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
The key players involved in the market are Amgen Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Limited.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER